drugset
drugset / Trial / NCT05872854

Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light

NCT05872854 ↗

Phase 2 Completed 10 enrolled Ellen Kim, MD Soligenix · collab
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to assess the benefit of continuous treatment with synthetic hypericin ointment (HyBryte) and visible light in patients with mycosis fungoides for up to 12 months (54 weeks). Funding Source: FDA OOPD.

Timeline

Start
2023-08-21
Primary completion
2025-12-22
Completion
2025-12-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Hypericin Other / unclassified 0.25 % Topical

Indications

mycosis fungoides